Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07594535 · ClinicalTrials.gov registry record · Phase 4
The Effect Of Lisinopril On Polycythemia
A Phase 4 study, sponsored by Mayo Clinic.
- Not yet
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT07594535: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT07594535 is a Phase 4 study that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07594535, a Phase 4 study, has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of the (angiotensin-converting enzyme) ACE inhibitor lisinopril on hemoglobin, hematocrit, and erythropoietin levels in patients with secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis. This study aims to determine whether ACE inhibition can effectively reduce excessive erythrocytosis by modulating erythropoietin production.
Interventions
- DRUG Lisinopril Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2029-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07594535
The ClinicalTrials.gov registry entry for NCT07594535 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lisinopril Tablets is the first listed.
NCT07594535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07594535 about?
NCT07594535 is a clinical study titled "The Effect Of Lisinopril On Polycythemia". The purpose of this study is to evaluate the effect of the (angiotensin-converting enzyme) ACE inhibitor lisinopril on hemoglobin, hematocrit, and erythropoietin levels in patients with secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other...
What is the current status of trial NCT07594535?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-07-01. Estimated completion is 2029-07-01.
What interventions are being tested in trial NCT07594535?
The interventions under investigation include: Lisinopril Tablets (DRUG).
Who is sponsoring clinical trial NCT07594535?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.